# Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

> **NCT03108131** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 49 (actual)

## Conditions studied

- Skin Squamous Cell Carcinoma
- Appendix Adenocarcinoma
- Rare Lesion
- Locally Advanced Malignant Neoplasm
- Locally Advanced Skin Squamous Cell Carcinoma
- Metastatic Malignant Neoplasm
- Metastatic Skin Squamous Cell Carcinoma
- Metastatic Small Intestinal Adenocarcinoma
- Rare Neoplastic Syndrome
- Refractory Malignant Neoplasm
- Stage IV Small Intestinal Adenocarcinoma AJCC v8
- Unresectable Malignant Neoplasm

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT03108131
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-07
- **Primary completion:** 2024-04-02
- **Final completion:** 2024-04-02
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03108131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03108131, "Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03108131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*